MorphoSys AG — Regulatory Filings 2001

Oct 17, 2001

News Details

Ad-hoc | 17 October 2001 07:30

MorphoSys AG english

MorphoSys Issued US Patent for HuCAL Antibody Library Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Issued US Patent for HuCAL Antibody Library MorphoSys AG (Neuer Markt: MOR), the Munich-based biotechnology company, announced today that the U.S. Patent & Trademark Office has granted the Company a new patent covering it’s Human Combinatorial Antibody Library (HuCAL). The U.S. patent (US 6,300,064), entitled “Protein/(poly)peptide libraries” covers methods for the construction of synthetic, fully modular human antibody libraries based on in silico consensus sequences. The application on which the patent is based was submitted to the U.S. Patent Office in 1998. A related HuCAL patent was issued in Australia in the year 2000, and further patent applications are currently pending in Canada, Europe and Japan. Recently another patent was granted to MorphoSys in the U.S. (US 6,294,353), entitled “Targeted hetero-association of recombinant proteins to multi- functional complexes”, further strengthening MorphoSys’ intellectual property portfolio. The patent covers multifunctional protein complexes formed by certain hetero-associating domains. To-date, MorphoSys has four patents granted and more than 40 applications pending worldwide. The patents and pending applications cover a variety of different technologies, including antibody libraries, screening methods such as the EST and CysDisplayTM technologies, certain antibody fragment formats, and specific antibodies. end of ad-hoc-announcement (c)DGAP 17.10.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 170730 Okt 01